enVVeno Medical Corp
NVNO
View Detailed Chart
10.420USD
+1.070+11.44%
Close 02/06, 16:00（ET）Quotes delayed by 15 min
6.02MMarket Cap
LossP/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
+11.44%
5 Days
-12.66%
1 Month
-19.54%
6 Months
+108.82%
Year to Date
-7.20%
1 Year
+235.05%
View Detailed Chart
TradingKey Stock Score of enVVeno Medical Corp
Currency: USD Updated: 2026-02-06Key Insights
enVVeno Medical Corp's fundamentals are relatively weak, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 184 out of 392 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Hold, with the highest price target at 12.50.In the medium term, the stock price is expected to trend down.Despite a very weak stock market performance over the past month, the company shows strong technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
enVVeno Medical Corp's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
enVVeno Medical Corp Highlights
StrengthsRisks
enVVeno Medical Corporation is a late clinical-stage medical device company. The Company is focused on the advancement of bioprosthetic (tissue-based) solutions to improve the standard of care for the treatment of venous disease. The Company is developing surgical and non-surgical replacement venous valves for patients suffering from severe chronic venous insufficiency (CVI) of the deep venous system of the leg. The Company’s lead product is the VenoValve, which is a surgical replacement venous valve that is being evaluated in a U.S. pivotal study. The VenoValve is implanted into the femoral vein of the patient in an open surgical procedure via a 5-to-6-inch incision in the upper thigh. The Company is also developing a second product called enVVe, which is a non-surgical, transcatheter-based replacement venous valve. Both the VenoValve and enVVe are designed to act as one-way valves, to help assist in propelling blood up the veins of the leg, and back to the heart and lungs.
Overvalued
The company’s latest PE is -0.28, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 169.95K shares, decreasing 28.78% quarter-over-quarter.
Held by James Simons
Star Investor James Simons holds 834.00 shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 8.32.
Analyst Rating
Based on
1
analysts
Hold
Current Rating
12.500
Target Price
+1517.29%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
enVVeno Medical Corp News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
enVVeno Medical Corp Info
enVVeno Medical Corporation is a late clinical-stage medical device company. The Company is focused on the advancement of bioprosthetic (tissue-based) solutions to improve the standard of care for the treatment of venous disease. The Company is developing surgical and non-surgical replacement venous valves for patients suffering from severe chronic venous insufficiency (CVI) of the deep venous system of the leg. The Company’s lead product is the VenoValve, which is a surgical replacement venous valve that is being evaluated in a U.S. pivotal study. The VenoValve is implanted into the femoral vein of the patient in an open surgical procedure via a 5-to-6-inch incision in the upper thigh. The Company is also developing a second product called enVVe, which is a non-surgical, transcatheter-based replacement venous valve. Both the VenoValve and enVVe are designed to act as one-way valves, to help assist in propelling blood up the veins of the leg, and back to the heart and lungs.
Ticker SymbolNVNO
CompanyenVVeno Medical Corp
CEOBerman (Robert A)
Websitehttps://envveno.com/
Related Instruments
+3.66%
+3.17%
+0.93%
+1.99%
+1.78%
+1.60%
-0.95%
+4.49%
+2.10%
+10.00%
+2.72%
+4.15%
+1.81%
+4.17%
+0.72%
+1.06%
+2.46%
0.00%
+0.53%
+0.56%Popular Symbols
278.120
+2.210 (+0.80%)
185.410
+13.530 (+7.87%)
67889.700
-2080.430 (-2.97%)
282.580
+22.390 (+8.61%)
2004.190
-47.540 (-2.32%)
411.110
+13.900 (+3.50%)
4952.980
+142.360 (+2.96%)
63.303
+0.206 (+0.33%)
1.182
+0.004 (+0.35%)
157.098
+0.057 (+0.04%)
